Prevalence of HLA-DRB1 genotype and altered Fas/Fas ligand expression in adrenocortical carcinoma

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 3, 2005, Pages 1768-1774

  Wolkersdörfer, Gernot W ^a,d   Marx, Christian ^a   Brown, John ^b   Schröder, Sabine ^c   Füssel, Monika ^a   Rieber, E Peter ^a   Kuhlisch, Eberhard ^a   Ehninger, Gerhard ^a   Bornstein, Stefan R ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; FAS LIGAND; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; FASLG PROTEIN, HUMAN; HLA-DRB1 ANTIGEN; MEMBRANE PROTEIN;

ADRENAL CORTEX ADENOMA; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CANCER CYTODIAGNOSIS; CANCER RISK; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENETIC CORRELATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIGAND BINDING; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ADOLESCENT; ADRENAL CORTEX TUMOR; GENETIC PREDISPOSITION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PRESCHOOL CHILD; PREVALENCE; RISK FACTOR;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; CHILD; CHILD, PRESCHOOL; FAS LIGAND PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 15944375860     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1406     Document Type: Article

References (70)

1. Harrison LE, Gaudin PB, Brennan MF 1999 Pathologic features of prognostic significance for adrenocortical carcinoma after curative resection. Arch Surg 134:181-185
2. Bornstein SR, Stratakis CA, Chrousos GP 1999 Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med 130:759-771
3. Terzolo M, Ali A, Osella G, Mazza E 1997 Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Arch Surg 132:914-919
4. Lopez JM, Fardella C, Arteaga E, Michaud P, Rodriguez JA, Cruz F 1990 Adrenal macrotumors diagnosed by computed tomography. J Endocrinol Invest 13:581-585
5. Sworczak K, Babniska A, Stanek A, Lewczuk A, Siekierska-Hellmann M, Blaut K, Drobinska A, Basinski A, Lachnski AJ, Czaplinska-Kalas H, Gruca Z 2001 Clinical and histopathological evaluation of the adrenal incidentaloma. Neoplasma 48:221-226
6. Tello R, Chaoui A, Hymphrey M, Fenlon H, Anastasia-Rubino L, DeCarvalho VL, Yucel EK 2001 Incidence of adrenal masses in patients referred for renal artery stenosis screening MR. Invest Radiol 36:518-520
7. Marx C, Wolkersdorfer GW, Brown JW, Scherbaum WA, Bornstein SR 1996 MHC class II expression: a new tool to assess dignity in adrenocortical tumours. J Clin Endocrinol Metab 81:4488-4491
8. Marx C, Bornstein SR, Wolkersdorfer GW, Peter M, Sippell WG, Scherbaum WA 1997 Relevance of major histocompatibility complex class II expression as a hallmark for the cellular differentiation in the human adrenal cortex. J Clin Endocrinol Metab 82:3136-3140
9. Ozdemirli M, El Khatib M, Foote LC, Wang JK, Marshak-Rothstein A, Rothstein TL, Ju ST 1996 Fas (CD95)/Fas ligand interactions regulate antigen-specific, major histocompatibility complex-restricted T/B cell proliferative responses. Eur J Immunol 26:415-419
10. Razvi ES, Jiang Z, Woda BA, Welsh RM 1995 Lymphocyte apoptosis during the silencing of the immune response to acute viral infections in normal, Ipr, and Bcl-2-transgenic mice. Am J Pathol 147:79-91
11. Wolkersdorfer GW, Lohmann T, Marx C, Schröder S, Pfeiffer R, Stahl H-D, Scherbaum WA, Chrousos GP, Bornstein SR 1999 Lymphocytes stimulate dehydroepiandrosterone production through direct cellular contact with adrenal zona reticularis cells: a novel mechanism of immune-endocrine interaction. J Clin Endocrinol Metab 84:4220-4227
12. Jackson R, McNicol AM, Farquharson M, Foulis AK 1988 Class II MHC expression in normal adrenal cortex and cortical cells in autoimmune Addison's disease. J Pathol 155:113-120
13. Martin MP, Roep BO, Smit JW, Martorell PM 2002 Autoimmunity in Addison's disease. Neth J Med 60:269-275
14. Bilbao JR, Martin-Pagola A, Perez DN, Calvo B, Vitoria JC, Vazquez F, Castano L 2003 HLA-DRB1 and MICA in autoimmunity: common associated alleles in autoimmune disorders. Ann NY Acad Sci 1005:314-318
15. Park YS, Sanjeevi CB, Robles D, Yu L, Rewers M, Gottlieb PA, Fain P, Eisenbarth GS 2002 Additional association of intra-MHC genes, MICA and D6S273, with Addison's disease. Tissue Antigens 60:155-163
16. Pani MA, Seidl C, Bieda K, Seissler J, Krause M, Seifried E, Usadel KH, Badenhoop K 2002 Preliminary evidence that an endogenous retroviral long-terminal repeat (LTR13) at the HLA-DQB1 gene locus confers susceptibility to Addison's disease. Clin Endocrinol (Oxf) 56:773-777
17. Myhre AG, Undlien DE, Lovas K, Uhlving S, Nedrebo BG, Fougner KJ, Trovik T, Sorheim JI, Husebye ES 2002 Autoimmune adrenocortical failure in Norway autoantibodies and human leukocyte antigen class II associations related to clinical features. J Clin Endocrinol Metab 87:618-623
18. Partanen J, Peterson P, Westman P, Aranko S, Krohn K 1994 Major histocompatibility complex class II and III in Addison's disease. MHC alleles do not predict autoantibody specificity and 21-hydroxylase gene polymorphism has no independent role in disease susceptibility. Hum Immunol 41:135-140
19. Weetman AP, Zhang L, Tandon N, Edwards OM 1991 HLA associations with autoimmune Addison's disease. Tissue Antigens 38:31-33
20. Greil R, Egle A, Villunger A 1998 On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model. Leuk Lymphoma 31:477-490
21. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F 1996 The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184:1075-1082
22. Wolkersdorfer GW, Marx C, Brown JW, Scherbaum WA, Bornstein SR 1996 Evaluation of apoptotic parameters in normal and neoplastic human adrenal. Endocr Res 22:411-419
23. Shen X, Konig R 1998 Regulation of T cell immunity and tolerance in vivo by CD4. Int Immunol 10:247-257
24. Boehme SA, Zheng L, Lenardo MJ 1995 Analysis of the CD4 coreceptor and activation-induced costimulatory molecules in antigen-mediated mature T lymphocyte death. J Immunol 155:1703-1712
25. Suda T, Takahashi T, Golstein P, Nagata S 1993 Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178
26. D'Alessio A, Riccioli A, Lauretti P, Padula F, Muciaccia B, De Cesaris P, Filippini A, Nagata S, Ziparo E 2001 Testicular FasL is expressed by sperm cells. Proc Natl Acad Sci USA 98:3316-3321
27. Sano Y, Sotozono C 2002 Role of Fas ligand in ocular tissue. Cornea 21:S30-S32
28. Choi C, Benveniste EN 2004 Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res Brain Res Rev 44:65-81
29. Kauma SW, Huff TF, Hayes N, Nilkaeo A 1999 Placental Fas ligand expression is a mechanism for maternal immune tolerance to the fetus. J Clin Endocrinol Metab 84:2188-2194
30. Xerri L, Devilard E, Hassoun J, Mawas C, Birg F 1997 Fas ligand is not only expressed in immune privileged human organs but is also coexpressed with Fas in various epithelial tissues. Mol Pathol 50:87-91
31. Martinez-Lorenzo MJ, Anel A, Alava MA, Pineiro A, Naval J, Lasierra P, Larrad L 2004 The human melanoma cell line MelJuSo secretes bioactive FasL and APO2L/TRAIL on the surface of microvesicles. Possible contribution to tumor counterattack. Exp Cell Res 295:315-329
32. Bornstein SR, Rutkowski H, Vrezas I 2004 Cytokines and steroidogenesis. Mol Cell Endocrinol 215:135-141
33. Gratas C, Tohma Y, Van Meir EG, Klein M, Tenan M, Ishii N, Tachibana O, Kleihues P, Ohgaki H 1997 Fas ligand expression in glioblastoma cell lines and primary asrrocytic brain tumors. Brain Pathol 7:863-869
34. Saas P, Walker PR, Hahne M, Quiquerez AL, Schnuriger V, Perrin G, French L, Van Meir EG, de Tribolet N, Tschopp J, Dietrich PY 1997 Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 99:1173-1178
35. Yokomizo H, Yoshimatsu K, Ishibashi K, Hashimoto M, Yosida K, Kato H, Naritaka Y, Okada Y, Ogawa K 2003 Fas ligand expression is a risk factor for liver metastasis in colorectal cancer with venous invasion. Anticancer Res 23:5221-5224
36. Belluco C, Esposito G, Bertorelle R, Alaggio R, Giacomelli L, Bianchi LC, Nitti D, Lise M 2002 Fas ligand is up-regulated during the colorectal adenomacarcinoma sequence. Eur J Surg Oncol 28:120-125
37. Shimoyama M, Kanda T, Liu L, Koyama Y, Suda T, Sakai Y, Hatakeyama K 2001 Expression of Fas ligand is an early event in colorectal carcinogenesis. J Surg Oncol 76:63-68
38. Fukuzawa K, Takahashi K, Furuta K, Tagaya T, Ishikawa T, Wada K, Omoto Y, Koji T, Kakumu S 2001 Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). J Gastroenterol 36:681-688
39. Lee SH, Shin MS, Lee HS, Bae JH, Lee HK, Kim HS, Kim SY, Jang JJ, Joo M, Kang YK, Park WS, Park JY, Oh RR, Han SY, Lee JH, Kim SH, Lee JY, Yoo NJ 2001 Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum Pathol 32:250-256
40. Nagao M, Nakajima Y, Hisanaga M, Kayagaki N, Kanehiro H, Aomatsu Y, Ko S, Yagita H, Yamada T, Okumura K, Nakano H 1999 The alteration of Fas receptor and ligand system in hepatocellular carcinomas: how do hepatoma cells escape from the host immune surveillance in vivo? Hepatology 30:413-421
41. O'Connell J, Bennett MW, O'Sullivan GC, O'Callaghan J, Collins JK, Shanahan F 1999 Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol 6:457-463
42. Takigawa N, Ida M, Segawa Y, Nakata M, Mandai K, Kishino D, Fujiwara K, Saeki H, Takashima S, Eguchi K 2003 Expression of cyclooxygenase-2, Fas and Fas ligand in pulmonary adenocarcinoma and atypical adenomatous hyperplasia. Anticancer Res 23:5069-5073
43. Weiss LM 1984 Comparative histologic study of 43 metastasizing and non-metastasizing adrenocortical tumors. Am J Surg Pathol 8:163-169
44. MacFarlane DA 1958 Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 23:155-186
45. Gazdar AF, Oie HK, Shackleton CH, Chen TR, Triche TJ, Myers CE, Chrousos GP, Brennan MF, Stein CA, La Rocca RV 1990 Establishment and characterization of a human adrenocortical carcinoma cell line that expresses multiple pathways of steroid biosynthesis. Cancer Res 50:5488-5496
46. Lange K 2004 Mathematical and statistical methods for genetic analysis. In: Gail M, Krickeberg K, Samet J, Tsiatis A, Wong W. Statistics for Biology and Health. 2nd ed. Heidelberg: Springer
47. Mori M, Beatty PG, Graves M, Boucher KM, Milford EL 1997 HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 64:1017-1027
48. Padgett DA, Loria RM 1994 In vitro potentiation of lymphocyte activation by dehydroepiandrosterone, androstenediol, and androstenetriol. J Immunol 153:1544-1552
49. Loria RM 2002 Immune up-regulation and tumor apoptosis by androstene steroids. Steroids 67:953-966
50. Maroto R, Shen X, Konig R 1999 Requirement for efficient interactions between CD4 and MHC class II molecules for survival of resting CD4+ T lymphocytes in vivo and for activation-induced cell death. J Immunol 162:5973-5980
51. Riberdy JM, Mostaghel E, Doyle C 1998 Disruption of the CD4-major histocompatibility complex class II interaction blocks the development of CD4(+) T cells in vivo. Proc Natl Acad Sci USA 95:4493-4498
52. Saff RR, Spanjaard ES, Hohlbaum AM, Marshak-Rothstein A 2004 Activation-induced cell death limits effector function of CD4 tumor-specific T cells. J Immunol 172:6598-6606
53. Wolkersdorfer GW, Ehrhart-Bornstein M, Brauer S, Marx C, Scherbaum WA, Bernstein SR 1996 Differential regulation of apoptosis in the normal human adrenal gland. J Clin Endocrinol Metab 81:4129-4136
54. Brocker T 1997 Survival of mature CD4 T lymphocytes is dependent on major histocompatibility complex class II-expressing dendritic cells. J Exp Med 186:1223-1232
55. Lee SH, Bar-Haim E, Goldberger O, Reich-Zeliger S, Vadai E, Tzehoval E, Eisenbach L 2004 Expression of FasL by tumor cells does not abrogate antitumor CTL function. Immunol Lett 91:119-126
56. Li ZY, Zou SQ 2001 Fas counterattack in cholangiocarcinoma: a mechanism for immune evasion in human hilar cholangiocarcinomas. World J Gasrroenterol 7:860-863
57. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T 2000 Frequency of apoptosis of tumor-infiltrating lymphocytes induced by fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin Cancer Res 6:3560-3564
58. Jekle A, Obst R, Lang F, Rammensee HG, Gulbins E 2000 CD95/CD95 ligand-mediated counterattack does not block T cell cytotoxicity. Biochem Biophys Res Commun 272:395-399
59. O'Connell J, Bennett MW, O'Sullivan GC, Roche D, Kelly J, Collins JK, Shanahan F 1998 Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J Pathol 186:240-246
60. Bennett MW, O'Connell J, O'Sullivan GC, Brady C, Roche D, Collins JK, Shanahan F 1998 The Fas counterattack in vivo: apoptotic depletion of tumor-infilrrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 160:5669-5675
61. O'Connell J, Bennett MW, O'Sullivan GC, Collins JK, Shanahan F 1997 The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 3:294-300
62. Lee SH, Shin MS, Park WS, Kim SY, Dong SM, Pi JH, Lee HK, Kim HS, Jang JJ, Kim CS, Kim SH, Lee JY, Yoo NJ 1999 Alterations of Fas (APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res 59:3068-3072
63. Takakuwa T, Dong Z, Takayama H, Matsuzuka F, Nagata S, Aozasa K 2001 Frequent mutations of Fas gene in thyroid lymphoma. Cancer Res 61:1382-1385
64. Gronbaek K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen J, Hou-Jensen K, Guldberg P 1998 Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92:3018-3024
65. O'Connell J, Bennett MW, Nally K, Houston A, O'Sullivan GC, Shanahan F 2000 Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-irnmune conflict. Ann NY Acad Sci 910:178-192
66. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS, Eberlein TJ 1999 Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 125:73-84
67. Que FG, Phan VA, Phan VH, Celli A, Batts K, LaRusso NF, Gores GJ 1999 Cholangiocarcinomas express Fas ligand and disable the Fas receptor. Hepatology 30:1398-1404
68. Concha A, Esteban F, Cabrera T, Ruiz-Cabello F, Ganido F 1991 Tumor aggressiveness and MHC class I and II antigens in laryngeal and breast cancer. Semin Cancer Biol 2:47-54
69. McDougall CJ, Ngoi SS, Goldman IS, Godwin T, Felix J, DeCosse JJ, Rigas B 1990 Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res 50:8023-8027
70. Ryu KS, Lee YS, Kim BK, Park YG, Kim YW, Hur SY, Kim TE, Kim IK, Kim JW 2001 Alterations of HLA class I and II antigen expression in preinvasive, invasive and metastatic cervical cancers. Exp Mol Med 33:136-144